Retroviral Integrase: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 28: | Line 28: | ||
==Mechanism for strand-transfer inhibition action== | ==Mechanism for strand-transfer inhibition action== | ||
==Integrase Inhibitors== | |||
== | |||
{| class="wikitable" | {| class="wikitable" | ||
| Line 35: | Line 34: | ||
|- | |- | ||
| [[Raltegravir]] || Isentress || [[Merck & Co.]] || - || also known as MK-0518. Raltegravir was approved by the FDA on October 12, 2007, for use with other anti-HIV agents in the treatment of HIV infection in adults. It is the first integrase inhibitor approved by the FDA. | | [[http://www.isentress.com/raltegravir/isentress/consumer/index.jsp Raltegravir]] || Isentress || [[Merck & Co.]] || - || also known as MK-0518. Raltegravir was approved by the FDA on October 12, 2007, for use with other anti-HIV agents in the treatment of HIV infection in adults. It is the first integrase inhibitor approved by the FDA. | ||
|- | |- | ||
| [[Elvitegravir]] || GS-9137 || [[Gilead Science]] || - || in experimental stages. Phase II studies of elvitegravir in people who are treatment experienced have been completed. Phase III studies in treatment experienced patients are ongoing. A phase II study of elvitegravir in people who have never taken antiretroviral therapy is underway. This study will also be evaluated a boosting agent in place of Norvir, currently called GS9350. Elvitegravir holds promise for HIV-positive patients who have taken other anti-HIV drugs in the past. | | [[Elvitegravir]] || GS-9137 || [[Gilead Science]] || - || in experimental stages. Phase II studies of elvitegravir in people who are treatment experienced have been completed. Phase III studies in treatment experienced patients are ongoing. A phase II study of elvitegravir in people who have never taken antiretroviral therapy is underway. This study will also be evaluated a boosting agent in place of Norvir, currently called GS9350. Elvitegravir holds promise for HIV-positive patients who have taken other anti-HIV drugs in the past. | ||
|- | |- | ||
|} | |||
==References== | ==References== | ||
